Dermatan sulfate - Opocrin

Drug Profile

Dermatan sulfate - Opocrin

Alternative Names: OP 435

Latest Information Update: 06 Jul 1998

Price : $50

At a glance

  • Originator Opocrin
  • Class Antithrombotics; Glycosaminoglycans; Small molecules
  • Mechanism of Action Glycosaminoglycan stimulants; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 06 Jul 1998 Discontinued-Preclinical for Thrombosis in USA (Injection)
  • 06 Jul 1998 Discontinued-Preclinical for Thrombosis in Italy (Injection)
  • 06 Jul 1998 Discontinued-Clinical for Thrombosis (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top